Slide 1: Exchange filing cover letter for investor presentation
26th July 2024 (1) BSE Ltd. (2) National Stock Exchange of India Ltd. Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor Dalal Street Plot no. C/1, G Block Mumbai 400 001 Bandra Kurla Complex Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip Code: CIPLA
Slide 2: Investor Presentation Q1FY25
Investor Presentation Q1FY25 26-07-2024 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Strong performance in focused markets; upward operating profitability trajectory
Strong performance1 in focused markets; upward operating profitability trajectory Revenue EBITDA PAT 14% (YoY) 17% (YoY) 7% INR 1,716 Cr INR 1,178 Cr Q1FY25 INR 6,694 Cr (YoY) 154 bps 156 bps 25.6% 17.6% of Revenue of Revenue Business Performance Snapshot Emerging Markets & One India North America S
Slide 5: Financial Performance – Q1FY25
Financial Performance1 – Q1FY25 Revenues INR 6,694 Cr EBITDA INR 1,716 Cr Revenue2 Break-up Q1FY25 (Consolidated) API, 2% Others, 1% Actuals vs Q1 FY24 (INR Cr) Emerging Markets & Europe, 13% Total Revenue from 6,694 7.0% Operations SAGA, EBITDA 1,716 13.8% 10% India, 43% EBITDA % 25.6% 154 bps PAT
Slide 6: Healthy Cash Position – Continued focus on building balance sheet strength
Healthy Cash Position – Continued focus on building balance sheet strength INR Cr Total Debt1 Cash Balance2 Net Cash3 8,996 8,449 8,267 7,591 7,708 7,143 559 547 449 Dec'23 Mar'24 Jun'24 Dec'23 Mar'24 Jun'24 Dec'23 Mar'24 Jun'24 1. Total debt includes lease liabilities and working capital loan| 2. C
Slide 7: Key Highlights of Q1FY25
Key Highlights of Q1FY25 India Branded Prescription – Launched generic version of Chronic share improved by Lanreotide injection ~100 bps YoY to 61.5%1 North America quarterly Patalganga & Kurkumbh facilities revenue at $ 250 Mn classified ‘VAI’ by USFDA South Africa prescription business Healthy Ne
Slide 8: One India: Driving long-term growth with a legacy of sustainability
One India1 : Driving long-term growth with a legacy of sustainability One India revenue trend Branded Prescription revenue trend TTM Jun-22 INR 8,964 Cr Q1FY23 INR 1,834 Cr CAGR2 CAGR TTM Jun-23 INR 10,162 Cr Q1FY24 INR 2,045 Cr 11% 11% TTM Jun-24 INR 10,992 Cr Q1FY25 INR 2,248 Cr Branded Prescripti
Slide 9: India Branded Prescription – Accelerating growth via focused approach
India Branded Prescription – Accelerating growth via focused approach Steady uptake in Chronic portfolio1 growth (%) Rank Market Sales and Growth2 1st INR ~900 Cr 18% YoY Respiratory 1.0 9.2 Urology 13.3 2nd INR ~370 Cr 17% YoY 15.0 Cardiac 10.5 11.3 7th INR ~470 Cr 19% YoY Market Growth Cipla Growt
Slide 10: Strategic offerings in chronic therapies across 'Continuum of Care'
Strategic offerings in chronic therapies across ‘Continuum of Care’ Cardiac Respiratory Digital Paramedic Counsellors Counsellors Patient support for heart failure risk Berok Zindagi: Partnership with Filter Copy Urology Diabetes Oncology Mitra: Engaging 80,000+ Breast Cancer Awareness BPH1 awarenes
Slide 11: Trade Generics – Building a future-fit business
Trade Generics – Building a future-fit business 15,000+ 150,000+ #1 5,500+ Chemist coverage India’s largest Trade Stockiest Network Pin codes serviced Generic business across India 500+ Retail field team (RTF) Distribution Model change Operational efficiencies Transition completed1 Enhanced control
Slide 12: Global Consumer Wellness Franchise demonstrating promising outcomes
Q1FY25: Global Consumer Wellness Franchise demonstrating promising outcomes One India : Revenue INR 378 Cr 2 2 1 2 2 Hydration Pain relief Cold & cough Nicotine Replacement Skin infection INR 80+ Cr INR 70+ Cr INR 45+ Cr INR 25+ Cr INR 15+ Cr South Africa : Revenue ZAR 394 Mn 3 Cough, cold & flu Cou
Slide 13: North America: Consistent growth trajectory backed by traction in key assets
North America: Consistent growth trajectory backed by traction in key assets $ Mn 13% 250 222 229 230 226 195 204 179 155 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Key Business Highlights • Highest ever quarterly revenue at $250 Mn with a growth of 13% YoY • Lanreotide 505(b)(2)
Slide 14: ANDA & NDA Portfolio & Pipeline (As on 30th Jun 2024)
ANDA & NDA Portfolio & Pipeline (As on 30th Jun 2024) 14 62 9 3 17 8 79 2 3 55 18 8 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs Cipla Ltd PEPFAR 1 Invagen Partnered ANDAs/NDAs 164 31 83 278 Approved Tentatively Under Approval Total ANDAs & NDAs Approved ANDAs
Slide 15: SAGA: South Africa Private growing 5x faster than the market
SAGA1: South Africa Private growing 5x faster than the market ZAR Mn $ Mn SAGA Revenue SA Private Revenue trend 1,044 8 939 20 19 833 12 50 56 Q1FY24 Q1FY25 Q1FY23 Q1FY24 Q1FY25 SA Private SA Tender Others (SSA & CGA) Market Segment2 Rank Share Cipla Growth Market Growth SA Key Highlights2 South Afr
Slide 16: Q1FY25: Emerging Markets & Europe and API
Q1FY25 : Emerging Markets & Europe and API Emerging Markets & Europe1 API $ Mn Revenue $ Mn $ Mn Revenue $ Mn 102 95 17 12 Q1FY24 Q1FY25 Q1FY24 Q1FY25 1. North Africa region from Emerging Markets will be classified under SAGA henceforth. 15
Slide 17: ESG Update
ESG Update Progress on ESG 33.6 % RE2 compared Baddi facility certified as zero waste to landfill with a 44 % waste to 9% in to landfill3 FY20 diversion rate of 99.56% Addition of solar rooftop with annual capacity of 0.7 mn units 61 % 28 % Waste GHG1 disposal Human right assessment in line with SA8
Slide 18: Profit and Loss statement summary (Reported)
Profit and Loss statement summary (Reported) INR Cr Particulars Q1FY25 Q1FY24 Revenue from sale of products 6,625 6,269 Other operating income 69 60 Income from operations 6,694 6,329 Material cost 2,193 2,237 Employee benefits expense 1,194 1,067 Other expenses 1,591 1,532 Total expenses 4,978 4,83
Slide 19: Balance Sheet (Reported)
Balance Sheet (Reported) INR Cr Key Balance Sheet Items Jun-24 Mar-24 Jun-23 Equity 28,058 26,802 24,620 Total Debt 547 559 803 Inventory 5,531 5,238 5,297 Cash and Cash Equivalents* 8,996 8,267 6,941 Trade Receivables 4,990 4,771 4,310 Trade Payables 2,742 2,474 2,741 Net Tangible Assets 6,210 6,04
Slide 20: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com Ajinkya Pandharkar Investor.Relations@cipla.com For more information please visit 19 www